Case report

Alveolar hemorrhage in the setting of COVID-19: Report of a successful vascular intervention and embolization ✪, ✪

Afshin Mohammadi, MD a, Behdad Boroofeh, MD b, Seyed Ali Mousavi-Aghdas, MD c, Mohammad Mirza-Aghazadeh-Attari, MD-MPH d,e,∗

a Department of Radiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran  
b Department of Internal Medicine, Urmia University of Medical Sciences, Urmia, Iran  
c Medical Imaging sciences research center, Tabriz University of Medical Sciences, Tabriz, Iran

A R T I C L E   I N F O
Article history:  
Received 6 April 2021  
Revised 12 April 2021  
Accepted 13 April 2021

Keywords:  
COVID-19  
Radiology  
Vascular intervention

A B S T R A C T

The coronavirus disease 2019 (COVID-19) is characterized by viral pneumonia with mild to moderate symptoms. Emerging studies suggest that some patients may experience uncommon complications, such as thrombotic or hemorrhagic episodes. Here we present a 59-year-old male patient who had a hemorrhage episode from a branch of the pulmonary arteries and was treated by interventional embolization. Our case report demonstrates the importance of early diagnosis of hemorrhagic complications of COVID-19 and the possible benefits of early vascular intervention.

© 2021 Published by Elsevier Inc. on behalf of University of Washington.  
This is an open access article under the CC BY-NC-ND license  
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

The viral pneumonitis caused by the coronavirus disease 2019 (COVID-19) is characterized by dyspnea, coughs, and radiologic signs such as diffuse ground-glass opacities [1]. With the dissemination of the virus worldwide, uncommon clinical presentations have also been suggested, such as rapidly progressive pneumonia, pulmonary thromboembolism, and the involvement of other body systems, with further abnormal clinical scenarios emerging as the disease further progresses [2]. Appropriate diagnostic and therapeutic interventions have remained a challenge for some of the conditions, which has warranted the involvement of other medical specialties. Radiologists have been at the front line of diagnosing COVID-19 as CT imaging has shown an optimal sensitivity and positive predictive value [3]. However, the emergence of certain conditions has further involved radiologists, specifically interventional radiologists, in managing COVID-19. Until now, treatment has consisted of anti-malarial drugs, anti-inflammatory drugs, anti-coagulation medication, antibiotics, and oxygen therapy with various means [4]. However, new complications have required new therapeutic procedures. Here we report a

∗ Acknowledgments: This study did not receive funding  
E-mail address: m.aghazadeh75@yahoo.com (M. Mirza-Aghazadeh-Attari).  
https://doi.org/10.1016/j.radcr.2021.04.034  
1930-0433/© 2021 Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
According to the patient’s history, he was admitted to the emergency department with frequent hemoptysis from 7 days ago. The patient had coughs and low-grade fever from 10 days before hospitalization and had self-quarantined himself for the past 7 days because of a positive polymerase chain reaction test for COVID-19.

On admission, the patient had stable vital signs. The physical examination showed a body temperature of 38°C, blood pressure of 130/80 mm Hg, a pulse of 100 beats per minute, respiratory rate of 22 breaths per minute, and oxygen saturation of 93% while the patient was breathing ambient air. Auscultation of both hemithorax showed diffuse rales and rhonchi. Other physical examinations were generally unremarkable.

The patient reported progressive dyspnea, which had culminated in the patient becoming bedridden most of the day. The patient also reported hemoptysis, which had started 7 days ago and had increased in frequency.

On the first day of admission, the patient further deteriorated, presenting with massive hemoptysis and had a reduction of blood hemoglobin level to 8.5 mg/dl from 15 mg/dl during 24 hours, and became hypoxic (80% oxygen saturation while on the nasal cannula). The second computed tomography revealed progression of lung involvement as extensive bilateral diffuse central and peripheral ground-glass opacities and alveolar consolidation was seen (Fig. 1).

The patient was admitted to the intensive care unit (ICU) and was treated with azithromycin 500 mg via orogastric tube daily and was started on hydroxychloroquine 400 mg loading dose followed by 200 mg twice daily for a 7-day course. According to our previous experience about thromboembolic events in COVID-19, further evaluation by computed tomo-
After Embolization, conservative treatment was continued. On the 30th day of admission, the patient’s clinical condition had improved. His blood oxygen saturation had increased to 94% while he was breathing ambient air; thus, Supplemental oxygen was discontinued. He was afebrile, and all symptoms had resolved with the exception of his cough, which had decreased in severity. The patient was discharged from the hospital on the 31st day of admission.

Discussion

In this case report, we discuss a patient who deteriorated because of an arterial hemorrhage from a bronchial artery. The patient was treated by vascular intervention and embolization.

Similar case reports have been published where patients reported hemorrhagic complications. Conti et al. reported 2 patients. The first patient was a 76-year-old male who was being treated with azithromycin, anti-viral drugs, steroids, and low molecular weight heparin (LMWH). Seven day’s from admission, the patient developed severe abdominal pain, a sudden fall of blood pressure to 80/60 mmHg, and a decrease in hemoglobin levels. CT image of the abdomen showed a collection anterior to the left iliopsoas muscle and signs of active bleeding. The second case was a 72-year-old female who had a femoral venous thrombosis and was put on a therapeutic dosage of LMWH. Ten day’s after admission, the patient developed similar symptoms to the first patient and two late enhanced spots suggestive of active hemorrhage. Both patients had normal prothrombin time (PT) and partial thromboplastin time (PTT) values during hospitalization. Both patients had hemorrhages from branches of the inferior epigastric arteries. The authors contributed the etiology of the bleeding to COVID-19, either by increasing intra-abdominal pressure while coughing or by causing diffuse endothelial damage related to a cytokine storm [5]. The authors did not correlate the bleeding to LMWH use. Lucatelli et al., however, reported a series of cases with massive hemorrhage in COVID-19 patients receiving Heparin. Almost all patients had intramuscular bleeding, 1 had intracranial bleeding, 1 had retroperitoneal bleeding, and 1 had splenic bleeding. The patients were either considered for interventional embolization of the bleeding vessels or were managed conservatively.

Although limited patients have been described with serious hemorrhagic complications in the respiratory system, autopsies of those dying from COVID-19 have shown that alveolar hemorrhages are a common finding in those dying and are interestingly accompanied by the inappropriate formation of thrombi [6]. This finding in pathology examination of human tissues could be supplemented with in vitro studies which clearly show a dysfunctional coagulation system and platelet function [7]. Furthermore, autopsies show signs of diffuse alveolar damage with a rich infiltrate of inflammatory cells, which could contribute to damage to small alveolar vessels [8,9]. This is not to undermine the existence of gross thrombi formation in the lungs of those deceased, accompanied by deep venous thrombosis [10]. These autopsies and clinical studies reporting PTE have been the basis for the inclusion of LMWH in the therapeutic regimen for COVID-19 patients [11]. But emerging evidence shows that COVID-19 patients are also at an increased risk for hemorrhages, thus necessitating thorough evaluation of patients for any signs of it.

Patient consent

Written informed consent was obtained from the patient.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.radcr.2021.04.034.

References

[1] Mohammadi A, Mohebbi I, Khademvatani K, Pirnejad H, Mirza-Aghazadeh J, Gharebaghi N, et al. Clinical and radiological characteristics of pediatric patients with COVID-19: focus on imaging findings. Jpn J Radiol 2020;38(10):987–92.
[2] Lovato A, de Filippis C. Clinical presentation of COVID-19: A systematic review focusing on upper airway symptoms. Ear Nose Throat J 2020;99(9):569–76.
[3] Kanne JP, Bai H, Bernheim A, Chung M, Haramati LB, Kallmes DF, et al. COVID-19 imaging: What we know now and what remains unknown. Radiology 2021:204522.
[4] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. Jama 2020;323(18):1824–36.
[5] Conti CB, Henchi S, Coppeta GP, Testa S, Grassia R. Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern? Eur J Intern Med 2020;77:147–9.
[6] Carasana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20(10):1135–40.
[7] de Oliveira Toledo SI, Nogueira LS, das Graças Carvalho M, Rios DRA, de Barros Pinheiro M. COVID-19: Review and hematologic impact. Clinica Chimica Acta 2020;510:170–6.
[8] Schaller T, Hirschbühl K, Burkhardt K, Braun G, Trepel M, Märkl B, et al. Postmortem examination of patients with COVID-19. Jama 2020;323(24):2518–20.
[9] Pourafkar L, Mirza-Aghazadeh-Attari M, Zarrintan A, Mousavi-Aghdas SA. Hypercoagulopathy of COVID-19: A review of the clinical experience, pathophysiology, and considerations in prophylaxis and treatment. Iran J Med Sci 2020.
[10] Deshpande C. Thromboembolic findings in COVID-19 autopsies: pulmonary thrombosis or embolism? Ann Intern Med 2020;173(5):394–5.
[11] Porfia A, Pola R. Venous thromboembolism and heparin use in covid-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines. J Thromb Thrombolysis 2020;50(1):68–71.